Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Avelumab with M1774 for the Treatment of Patients with ARID1A-Mutated Recurrent Endometrial Cancer who have Received Prior Immunotherapy

Trial Status: closed to accrual

This phase II trial tests how well avelumab in combination with M1774 work together for treating patients with ARID1A-mutated endometrial cancer that has come back (recurrent) after receiving prior immunotherapy. Avelumab is a drug that binds to a protein called PD-L1 on tumor cells to block its ability to bind to other proteins found on T cells of the immune system. This blocking can help the immune system kill tumor cells. M1774 is a drug called an ATR-inhibitor, which prevents the growth of tumor cells by limiting their ability to repair damaged deoxyribonucleic acid (DNA). Giving avelumab and MI774 together may be safe, tolerable, and/or effective in treating patients with ARID1A-mutated recurrent endometrial cancer who have received prior immunotherapy.